Table 4.
Mayo Clinic (2004) Integrating European Collaborative Study 3B Staging |
Mayo Clinic (2012) |
||||||||
---|---|---|---|---|---|---|---|---|---|
Risk Factors | Risk Factors Present (n) | Stage | Patients (%) | Median OS (months) | Risk Factors | Risk Factors Present (n) | Stage | Patients (%) | Median OS (Months) |
cTnT >0.035 ng/mL NT-proBNP >332 pg/mL |
0 | 1 | 33 | 86 | cTnT >0.025 ng/mL NT-proBNP >1,800 pg/mL dFLC >180 mg/L |
0 | 1 | 25 | 94.1 |
1 | 2 | 30 | 43 | 1 | 2 | 27 | 40.4 | ||
2 | 3A | 18 | 17 | 2 | 3 | 25 | 14 | ||
NT-proBNP ≥8,500 pg/mL | 3B | 19 | 4.6 | 3 | 4 | 23 | 5.8 |